Effects of components derived from HPLC purification of human satietin on ingestion, body weight, and taste aversion in the rat.
The putative satiety agent human satietin (h-SAT) once thought to be homogenous has been separated by high-performance liquid chromatography (HPLC) into components designated peak A (P-A, 53%/w) and Peak B (P-B, 47%/w); P-B contains a putative satiety agent. In Experiment 1, male Sprague-Dawley rats were divided into six (n = 9-11) groups (Grps) and ICV infused: Grp 1, artificial cerebrospinal fluid (a-CSF), 10 microliters/rat; Grp 2, albumin (ALB), 53 micrograms/rat; Grp 3, semipurified (sp) h-SAT (parent compound), 100 micrograms/rat; Grp 4, P-A, 53 micrograms/rat; Grp 5, P-B, 47 micrograms/rat; and Grp 6, P-A+B, 53+47 micrograms/rat, respectively. Compared to Grp 1, food intake, the first day postinfusion, was suppressed in Grp 3 (p < 0.01) and equally attenuated (p < 0.06) in Grps 5 and 6. Body weight remained suppressed (p < 0.05) in Grps 3, 5, and 6 for 3 days and in Grps 3 and 6 (p < 0.05) for an additional 3 days; Grps 2 and 4 did not differ from Grp 1. These data show P-B suppresses food intake comparably to P-A+B and causes a prolonged weight loss. In Experiment 2, sph-SAT and a recombination of P-A and P-B was tested for aversiveness using the two-bottle test. Both sph-SAT and P-A+B significantly suppressed food intake, but only sph-SAT was found to be aversive. These data show that most likely during HPLC processing of sph-SAT an aversive component was lost.
Bellinger
L L
LL
Biomedical Sciences Department, Baylor College of Dentistry, Dallas, TX 75246.
Mendel
V E
VE
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001067:Appetite Depressants / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects*; D002851:Chromatography, High Pressure Liquid; D004326:Drinking / Q000187:drug effects; D004435:Eating / Q000187:drug effects*; D006020:Glycopeptides / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D007276:Injections, Intraventricular; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013649:Taste / Q000187:drug effects*
D001067:Appetite Depressants; D006020:Glycopeptides; D000804:Angiotensin II; C035102:satietin